Cristina Cismaru 1, Doina Tățulescu 1, M. Lucan 2, Adriana Slavcovici 2
1 Clinica de Boli Infecțioase, Cluj-Napoca
2 Institutul de Urologie și Transplant Renal, Cluj-Napoca
Abstract
CMV is an important pathogen in renal transplant recipients due to both direct and indirect effects. Infection presents most often as asymp tomatic viremia or with fever and neut ropen ia – CMV synd rome. Indir ect effects are: supressing of host defenses and predisposing to secondary infections with fungus and bact eria. Prevention must be individualized by risk group and im munosuppr essive regimen . The standard therapy in CMV disease is with ganciclovir. Alternative therapies includ e foscarnet, cidofovir, leflun omide. The role of valganciclovir in treatment of invasive disease is on study.